Literature DB >> 23063820

IVF versus ICSI for the fertilization of in-vitro matured human oocytes.

M Walls1, S Junk, J P Ryan, R Hart.   

Abstract

Traditional dogma suggests that intracytoplasmic sperm injection (ICSI) should be performed to ensure successful oocyte fertilization in an in-vitro maturation (IVM) cycle. This study postulated that there would be no difference in the fertilization rate when ICSI was compared with IVF. This hypothesis was tested in a randomized trial of IVF versus ICSI in IVM. A total of 150 immature oocytes were collected in eight cycles of IVM for patients diagnosed with polycystic ovarian syndrome (PCOS). Patients were primed with minimal FSH before transvaginal oocyte aspiration. Sibling oocytes were inseminated by 50% IVF and 50% ICSI. There was no significant difference in fertilization, useable or total blastocyst development between the two insemination technique groups. Clinical pregnancy results for combined fresh and cryopreserved transfers were identical between the two insemination techniques with a total of two fresh and five cryopreserved IVF-inseminated embryos resulting in three clinical pregnancies (42.9%) and five fresh and two cryopreserved ICSI-derived embryos resulting in three clinical pregnancies (42.9%). This research has shown IVF to be a legitimate fertilization technique for IVM oocytes in PCOS patients and provides a greater awareness of the use of a fertilization method previously not utilized with IVM. In-vitro maturation (IVM) is an alternative treatment method to traditional IVF. Due to the minimal use of stimulating hormones in this treatment, IVM has a lower risk of ovarian hyperstimulation syndrome, it can be used for fertility preservation in cancer patients and it is more cost conservative. Early research into the effects of IVM showed a hardening effect on the membrane surrounding the egg (the zona pellucida). It was initially believed that, to overcome this hardening in order to allow the egg to be fertilized, spermatozoa would need to be injected into the egg using intracytoplasmic sperm injection. Due to recent advances in hormonal stimulation protocols (FSH priming) and culture conditions, we postulated that, for patients suffering from polycystic ovarian syndrome (PCOS), fertilization, embryo development and clinical pregnancy would not be superior in the injected oocytes compared with those inseminated by IVF. We found that by using the two insemination techniques on sibling oocytes from eight PCOS patients, there was no significant difference in fertilization, useable or total blastocyst development (day 5 or 6 embryos) and that clinical pregnancy results were identical. This research provides a greater awareness of a fertilization technique which is not normally utilized for IVM treatment, providing a less invasive, more cost-effective approach for the patient.
Copyright © 2012 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23063820     DOI: 10.1016/j.rbmo.2012.08.001

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  16 in total

1.  Retrievable hydrogels for ovarian follicle transplantation and oocyte collection.

Authors:  Peter D Rios; Ekaterina Kniazeva; Hoi Chang Lee; Shuo Xiao; Robert S Oakes; Eiji Saito; Jacqueline S Jeruss; Ariella Shikanov; Teresa K Woodruff; Lonnie D Shea
Journal:  Biotechnol Bioeng       Date:  2018-05-14       Impact factor: 4.530

2.  Mosaic embryo transfer after oocyte in vitro maturation in combination with non-invasive prenatal testing (NIPT)-first report of a euploid live birth.

Authors:  Naomi Inoue; Rosmary Lopez; Andrea Delgado; Denisse Nuñez; Jimmy Portella; Luis Noriega-Hoces; Luis Guzmán
Journal:  J Assist Reprod Genet       Date:  2017-06-24       Impact factor: 3.412

3.  Vitrification of in vitro matured oocytes: effects on meiotic spindle configuration and mitochondrial function.

Authors:  Tao Lei; Na Guo; Jie-Qiong Liu; Mei-Hua Tan; Yu-Feng Li
Journal:  Int J Clin Exp Pathol       Date:  2014-02-15

4.  Day 5 versus Day 6 blastocyst transfers: a systematic review and meta-analysis of clinical outcomes.

Authors:  Mathilde Bourdon; Khaled Pocate-Cheriet; Astri Finet de Bantel; Veronika Grzegorczyk-Martin; Aureli Amar Hoffet; Elisangela Arbo; Marine Poulain; Pietro Santulli
Journal:  Hum Reprod       Date:  2019-10-02       Impact factor: 6.918

Review 5.  Dopamine agonists for preventing ovarian hyperstimulation syndrome.

Authors:  Huilin Tang; Selma Mourad; Suo-Di Zhai; Roger J Hart
Journal:  Cochrane Database Syst Rev       Date:  2016-11-30

6.  Transporting cumulus complexes using novel meiotic arresting conditions permits maintenance of oocyte developmental competence.

Authors:  Nicolas W Santiquet; Jason R Herrick; Angelica Giraldo; Jennifer P Barfield; William B Schoolcraft; Rebecca L Krisher
Journal:  J Assist Reprod Genet       Date:  2017-06-01       Impact factor: 3.412

7.  Comparison of blastocyst and Sage media for in vitro maturation of human immature oocytes.

Authors:  Pallop Pongsuthirak; Sorramon Songveeratham; Teraporn Vutyavanich
Journal:  Reprod Sci       Date:  2014-07-11       Impact factor: 3.060

8.  Dopamine agonists for preventing ovarian hyperstimulation syndrome.

Authors:  Huilin Tang; Selma M Mourad; Aihua Wang; Suo-Di Zhai; Roger J Hart
Journal:  Cochrane Database Syst Rev       Date:  2021-04-14

9.  Birth of healthy offspring following ICSI in in vitro-matured common marmoset (Callithrix jacchus) oocytes.

Authors:  Tsukasa Takahashi; Kisaburo Hanazawa; Takashi Inoue; Kenya Sato; Ayako Sedohara; Junko Okahara; Hiroshi Suemizu; Chie Yagihashi; Masafumi Yamamoto; Tomoo Eto; Yusuke Konno; Hideyuki Okano; Makoto Suematsu; Erika Sasaki
Journal:  PLoS One       Date:  2014-04-21       Impact factor: 3.240

10.  In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction.

Authors:  Charalampos S Siristatidis; Abha Maheshwari; Dennis Vaidakis; Siladitya Bhattacharya
Journal:  Cochrane Database Syst Rev       Date:  2018-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.